ANTX

AN2 Therapeutics, Inc.

AN2 Therapeutics, Inc. (ANTX) has 17 SEC Form 4 filings (17 transaction rows) in the rolling window, disclosed by 2 distinct insiders. Most recent filing: Jul 10, 2026.

  • Industry:Biotechnology
  • CEO:Eric E. Easom
  • Employees:22
  • HQ:Menlo Park, CA, US
  • IPO:2022-03-25

Insider Buying

$0

reported purchases (SEC code P)

Insider Selling

$26K

reported sales (SEC code S)

Unique Insiders

2

in the rolling window

Market Cap

$213.6M

latest known value

Source
Eizen Joshua MFirst filing
Sale$25KJul 10SEC ↗
Sale$1KJun 2SEC ↗
Sale$347Mar 5SEC ↗

Related companies

AN2 Therapeutics, Inc. is in the Healthcare sector.